All News
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
David Liew drdavidliew ( View Tweet)
#OP0279 #EULAR2022 Let's start with N=5! Promising new therapy CAR T-cell in #lupus. All patients were refractory to various therapies and had active nephritis. Post-treatment, all responded clinically and serologically! Need to go to RCT next @RheumNow https://t.co/RaTlVALQqn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis
https://t.co/k61KOBXRSl
#EULAR2022 https://t.co/Q7cjqvQyFG
Links:
Dr. John Cush RheumNow ( View Tweet)
Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study
#EULAR2022
>CR https://t.co/AgBBuqYatW
ARD & RMD Open ARD_BMJ ( View Tweet)
WIN-Lupus. RCT of stopping treatment in SLE. All on HCQ. Randomised to stop Aza/MMF after being stable on for 2-3 years. Relapse proliferative nephritis in 25% vs 10%. Severe SLE flare 32% vs 13%. @RheumNow #EULAR2022 OP0280 https://t.co/IAcCoKw1YI
Links:
Richard Conway RichardPAConway ( View Tweet)
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Links:
Richard Conway RichardPAConway ( View Tweet)
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Links:
Richard Conway RichardPAConway ( View Tweet)
#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Schett et al. CAR-T in SLE, case series 4 patients. Effective in inducing clinical remission in all 4 refractory patients. Looks like #rheummadness may have been (almost) correct @DavidLeverenz ! @RheumNow #EULAR2022 OP0279 https://t.co/frAU8COFs8
Links:
Richard Conway RichardPAConway ( View Tweet)
More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf
TheDaoIndex KDAO2011 ( View Tweet)
Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb
TheDaoIndex KDAO2011 ( View Tweet)
#PEARLS by Dr. Werth:
1. anti-malarials only work 50% of time for cutaneous lupus (CLE).
2. AZP is not as effective as MTX or MMF for #CLE
3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ
TheDaoIndex KDAO2011 ( View Tweet)
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
David Liew drdavidliew ( View Tweet)
#PEARLS by EULAR President Prof Iagnocco:
1. Enthesitis can be present in 25% of #SLE patients
2. Erosions can be common and independent of ACPA/RF status
3. Active myositis is indistinguishable from IIM
4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve
TheDaoIndex KDAO2011 ( View Tweet)
Staggering facts by Prof Vital on #SLE and SkM Sx’s:
- 50% of first Sx’s is SkM
- SkM Sx are in top 3 concerns for pts
- 34% pts w/SkM Sx stopped working median 4 yrs
- SkM damage clusters with CVD damage
#EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ
TheDaoIndex KDAO2011 ( View Tweet)
“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U
TheDaoIndex KDAO2011 ( View Tweet)
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
TheDaoIndex KDAO2011 ( View Tweet)
OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
